Press release
Idiopathic Pulmonary Fibrosis Pipeline Outlook Report 2024 (Updated)
Idiopathic Pulmonary Fibrosis Pipeline
Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report
• DelveInsight's Idiopathic Pulmonary Fibrosis pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Idiopathic Pulmonary Fibrosis treatment.
• The leading companies working in the Idiopathic Pulmonary Fibrosis Market include FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical, and others.
• Promising Idiopathic Pulmonary Fibrosis Pipeline Therapies in the various stages of development include DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitil, AP01, BBT-877, and others.
• December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for BMS-986278. The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
• December 2023: United Therapeutics announced a study of Phase 3 clinical trials for Inhaled Treprostinil. Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.
• November 2023: Modern Biosciences Ltd. announced a study of Phase 2 clinical trials for Leramistat. This will be a Phase 2, double-blind, placebo-controlled, 2-arm, parallel-group, multi-centre study to investigate leramistat treatment of patients aged 40 years or older with IPF.
Request a sample and discover the recent advances in Idiopathic Pulmonary Fibrosis Treatment Drugs @ Idiopathic Pulmonary Fibrosis Pipeline Report- https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Idiopathic Pulmonary Fibrosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Idiopathic Pulmonary Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Idiopathic Pulmonary Fibrosis Overview
Idiopathic pulmonary fibrosis (IPF) is a lung disorder where there is scarring of the lungs from an unknown cause. It is usually a progressive disease with a poor long-term prognosis. The classic features of the disorder include progressive dyspnea and a nonproductive cough. Pulmonary function tests usually reveal restrictive impairment and diminished carbon monoxide diffusing capacity.
Find out more about Idiopathic Pulmonary Fibrosis Treatment Landscape @ Drugs for Idiopathic Pulmonary Fibrosis Treatment- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Idiopathic Pulmonary Fibrosis Emerging Drugs Profile
• Pamrevlumab: FibroGen
• Tipelukast: MediciNova
• PLN-74809: Pliant Therapeutics
• HZN-825: Horizon Pharmaceuticals
• Brilaroxazine: Reviva Pharmaceuticals
Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment
There are approx. 80+ key companies which are developing the therapies for Idiopathic Pulmonary Fibrosis. The Idiopathic Pulmonary Fibrosis companies which have their Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage, i.e. phase III include, FibroGen.
DelveInsight's Idiopathic Pulmonary Fibrosis Pipeline Report covers around 80+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Learn more about the emerging Idiopathic Pulmonary Fibrosis Pipeline Therapies @ Idiopathic Pulmonary Fibrosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report
• Coverage- Global
• Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Idiopathic Pulmonary Fibrosis Companies- FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical, and others.
• Idiopathic Pulmonary Fibrosis Pipeline Therapies- DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitil, AP01, BBT-877, and others.
Dive deep into rich insights for new drugs for Idiopathic Pulmonary Fibrosis Treatment, Visit @ Idiopathic Pulmonary Fibrosis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Idiopathic Pulmonary Fibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Idiopathic Pulmonary Fibrosis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. PRM-151: Hoffmann-La Roche
9. Mid Stage Products (Phase II)
10. Tipelukast: MediciNova
11. Early Stage Products (Phase I/II)
12. Lung stem cells: Regend Therapeutics
13. Early Stage Products (Phase I)
14. LTI-03: Lung Therapeutics
15. Preclinical and Discovery Stage Products
16. AD-214: Adalta
17. Inactive Products
18. Idiopathic Pulmonary Fibrosis Key Companies
19. Idiopathic Pulmonary Fibrosis Key Products
20. Idiopathic Pulmonary Fibrosis- Unmet Needs
21. Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
22. Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
23. Idiopathic Pulmonary Fibrosis Analyst Views
24. Idiopathic Pulmonary Fibrosis Key Companies
25. Appendix
For further information on the Idiopathic Pulmonary Fibrosis Pipeline Therapeutics, reach out @ Idiopathic Pulmonary Fibrosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://theventurecation.com/author/germanydennydones/
https://blogstudiio.com/fabry-disease-market-size/
https://meccapost.com/author/germanydennydones/
https://kitmaker.net/profile/yashveer-bhardwaj
http://www.costaricajobsearch.com/author/germanydennydones/
https://keralaclick.com/classified-advertising/user/profile/182882
https://aviator.forex.pm/?qa=user/germanydennydones
https://careers.coloradopublichealth.org/employers/2926283-delveinsight
https://www.heavyironjobs.com/profiles/4448319-denny-dones
https://jobs.blooloop.com/employers/2614577-delveinsight
https://www.animaljobsdirect.com/employers/2926436-delveinsight
https://jobs.windomnews.com/employers/2926467-delveinsight
https://jobs.fsoma.org/employers/2926471-delveinsight
https://jobs.thetab.com/employers/1458246-delveinsight
https://forum.squarespace.com/profile/421527-dennydonesgermany/?tab=field_core_pfield_1
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Idiopathic Pulmonary Fibrosis Pipeline Outlook Report 2024 (Updated) here
News-ID: 3443168 • Views: …
More Releases from DelveInsight Business Research LLP
Hidradenitis Treatment Market Size Report 2032: Emerging Drugs, Companies, Clini …
DelveInsight's "Hidradenitis Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Hidradenitis, historical and forecasted epidemiology as well as the Hidradenitis market trends in the United States.
Discover which therapies are expected to grab the Hidradenitis Market Share @ Hidradenitis Market Outlook- https://www.delveinsight.com/sample-request/hidradenitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Hidradenitis Market Report
• In March 2025:- UCB Biopharma SRL announced a study is to evaluate the safety of long-term…
Mastocytosis Treatment Market Size Report 2032: Emerging Drugs, Companies, Clini …
DelveInsight's "Mastocytosis Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Mastocytosis, historical and forecasted epidemiology as well as the Mastocytosis market trends in the United States.
Discover which therapies are expected to grab the Mastocytosis Market Share @ Mastocytosis Market Outlook- https://www.delveinsight.com/sample-request/mastocytosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Mastocytosis Market Report
• In February 2025:- Blueprint Medicines Corporation announced a study is to evaluate the long-term safety of…
Lamellar Ichthyosis Treatment Market Size Report 2032: Emerging Drugs, Companies …
DelveInsight's "Lamellar Ichthyosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lamellar Ichthyosis, historical and forecasted epidemiology as well as the Lamellar Ichthyosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover Key Insights into the Lamellar Ichthyosis Market with DelveInsight's In-Depth Report @ Lamellar Ichthyosis Market Size- https://www.delveinsight.com/sample-request/lamellar-ichthyosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Lamellar Ichthyosis Market Report
• In February…
Dyschromia Treatment Market Size Report 2032: Emerging Drugs, Companies, Clinica …
DelveInsight's "Dyschromia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dyschromia, historical and forecasted epidemiology as well as the Dyschromia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Dyschromia Market Share @ Dyschromia Market Outlook- https://www.delveinsight.com/sample-request/dyschromia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Dyschromia Market Report
• The increase in Dyschromia Market Size is a…
More Releases for Idiopathic
Idiopathic Pulmonary Fibrosis Market Size & Share Analysis
The new report published by The Business Research Company, titled Idiopathic Pulmonary Fibrosis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $3.89…
Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry.
The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,…
Idiopathic Membranous Nephropathy Treatment Market to Witness Significant Growth …
Idiopathic membranous nephropathy a glomerular disease usually of abrupt onset and associated with the nephrotic syndrome. Membranous nephropathy occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria).
R&D in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic membranous nephropathy treatment market. In…
Global Idiopathic Scoliosis Treatment Market Size by Type (Infantile Idiopathic, …
Global Idiopathic Scoliosis Treatment Market Research report provides vital information related to the overall market and forecast from 2019 to 2026. This report includes the in-depth analysis of market size, share, growth, trends and regional demand and top layers the Idiopathic Scoliosis Treatment Market. The major players dominating the market are focused upon throughout the by analyzing their revenue, their business summary, product segmentation along with the latest developments.
Get Sample…
Chronic Idiopathic Constipation Market Research Report 2024
Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipation…
Idiopathic Pulmonary Fibrosis - Epidemiology Forecast To 2025
Summary
The American Thoracic Society (ATS) defines IPF as a chronic, fibrosing interstitial pneumonia of unknown cause, which occurs primarily in older adults. IPF is characterized by variable degrees of inflammation and scarring and is associated with a histologic or radiologic pattern of usual interstitial pneumonia (UIP). IPF is the most common form of idiopathic interstitial pneumonia, having the worst prognosis, and only three to five years of median survival. IPF…
